NCT04867720View on ClinicalTrials.gov

Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients

PHASE4UnknownINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

October 10, 2022

Study Completion Date

February 22, 2023

Conditions

Liver Transplant

Interventions

DRUG

Everolimus

\- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hosipital, Seoul